Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
Background and objective: Best-value biological medicines may generate competition in the off-patent biologicals market, resulting in having more resources available to provide patients with access to necessary medicines while maintaining high-quality care. Belgium is a country known to have low bio...
Main Authors: | Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Isabelle Huys |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.644187/full |
Similar Items
-
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
by: Yannick Vandenplas, et al.
Published: (2021-02-01) -
Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices
by: Liese Barbier, et al.
Published: (2021-05-01) -
Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
by: Liese Barbier, et al.
Published: (2021-06-01) -
Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
by: Evelien Moorkens, et al.
Published: (2020-01-01) -
Biologicals and Biosimilars in Hematology: The Case of Rituximab
by: Arnold G. Vulto
Published: (2019-12-01)